Entries of Campone, M. on the publication server

Stupp, R., Tosoni, A., Bromberg, J. E. C., Hau, Peter, Campone, M., Gijtenbeek, J., Frenay, M., Breimer, L., Wiesinger, H., Allgeier, A., van den Bent, M. J. , Bogdahn, Ulrich, van der Graaf, W. , Yun, H. J., Gorlia, T., Lacombe, D. and Brandes, A. A. (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22 (9), pp. 2144-2149. Fulltext not available.

Reardon, D. A., Dresemann, G., Taillibert, S., Campone, M., van den Bent, M. , Clement, P., Blomquist, E., Gordower, L., Schultz, H., Raizer, J., Hau, Peter, Easaw, J., Gil, M., Tonn, J., Gijtenbeek, A., Schlegel, U., Bergstrom, P., Green, S., Weir, A. and Nikolova, Z. (2009) Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British journal of cancer 101 (12), pp. 1995-2004. Fulltext not available.

Stupp, R., Tosoni, A., Taal, W., Hau, P., Campone, M., Gijtenbeek, J., Frenay, M. P., Gorlia, T., Lacombe, D. and Brandes, A. A. (2008) Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061. Journal of Clinical Oncology 26 (15_sup), p. 2015. Fulltext not available.